The white paper takes a closer look at funding strategies for companies launching products for the first time. Does partnering or "Going it Alone" make more sense for emerging companies? Findings of the 2006-2015 analysis and implications for research companies, their potential large pharma commercialization partners, and venture capitalists are discussed.